VWA
VRTX icon

Valued Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Valued Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2K Sell
35
-2
-5% -$886 0.01% 222
2026
Q1 		$16.4K Sell
37
-7
-16% -$3.26K 0.01% 204
2025
Q4 		$19.9K Sell
44
-9
-17% -$3.88K 0.01% 160
2025
Q3 		$20.7K Sell
53
-16
-23% -$6.69K 0.01% 145
2025
Q2 		$30.7K Sell
69
-1
-1% -$461 0.02% 120
2025
Q1 		$33.9K Buy
70
+14
+25% +$6.52K 0.02% 115
2024
Q4 		$22.6K Buy
56
+5
+10% +$2.32K 0.01% 143
2024
Q3 		$23.7K Buy
51
+8
+19% +$3.84K 0.02% 133
2024
Q2 		$20.2K Buy
43
+3
+8% +$1.3K 0.01% 133
2024
Q1 		$16.7K Buy
40
+19
+90% +$8.03K 0.01% 139
2023
Q4 		$7.3K Buy
+21
New +$7.76K 0.01% 155

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Valued Wealth Advisors's VRTX Position: Q2 2026 in Review

Valued Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 5.4% in Q2 2026, selling an estimated $886 and leaving 35 shares worth $17.2K. The position accounts for 0.01% of the portfolio, ranked #222.

Valued Wealth Advisors first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $33.9K in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Valued Wealth Advisors held 35 shares of Vertex Pharmaceuticals worth $17.2K as of Q2 2026.
  • Valued Wealth Advisors sold 2 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886.
  • Vertex Pharmaceuticals made up 0.01% of Valued Wealth Advisors's portfolio in Q2 2026, its #222 holding.
  • Valued Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Valued Wealth Advisors's Vertex Pharmaceuticals position peaked at $33.9K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Valued Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.